SGLT2 inhibition and renal urate excretion: Role of luminal glucose, GLUT9, and URAT1

American Journal of Physiology - Renal Physiology

Volumn 316, Issue 1, 2019, Pages F173-F185

  Novikov, Aleksandra ^a   Fu, Yiling ^a   Huang, Winnie ^a   Freeman, Brent ^a   Patel, Rohit ^a   van Ginkel, Charlotte ^a   Koepsell, Hermann ^b   Busslinger, Meinrad ^c   Onishi, Akira ^a   Nespoux, Josselin ^a   Vallon, Volker ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

GLUT9; Proximal tubule; Sodium glucose cotransport; URAT1; Urate transport

Indexed keywords

CANAGLIFLOZIN; CREATININE; GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 9; MESSENGER RNA; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; URATE; URATE TRANSPORTER; ORGANIC ANION TRANSPORTER; SLC22A12 PROTEIN, MOUSE; SLC2A9 PROTEIN, MOUSE; SLC5A2 PROTEIN, MOUSE; URIC ACID; URICOSURIC AGENT;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE CLEARANCE; GENE; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; GLUCOSE URINE LEVEL; KIDNEY TUBULE ABSORPTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENAL CLEARANCE; SGLT1 GENE; SGLT2 GENE; URAT1 GENE; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; URINARY EXCRETION; URINE SAMPLING; ANIMAL; C57BL MOUSE; DRUG EFFECT; GENETICS; GENOTYPE; KIDNEY PROXIMAL TUBULE; KNOCKOUT MOUSE; METABOLISM; PHARMACOLOGY; PHENOTYPE; URINE;

ANIMALS; CANAGLIFLOZIN; GENOTYPE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; KIDNEY TUBULES, PROXIMAL; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGANIC ANION TRANSPORTERS; PHENOTYPE; RENAL ELIMINATION; RENAL REABSORPTION; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; URIC ACID; URICOSURIC AGENTS;

EID: 85059928982     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00462.2018     Document Type: Article

References (39)

1. Andrade JA, Kang HC, Greffin S, Garcia Rosa ML, Lugon JR. Serum uric acid and disorders of glucose metabolism: the role of glycosuria. Braz J Med Biol Res 47: 917–923, 2014. doi:10.1590/1414-431X20143878.
2. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagli-flozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223–2233, 2010. doi:10.1016/S0140-6736(10)60407-2.
3. Bibert S, Hess SK, Firsov D, Thorens B, Geering K, Horisberger JD, Bonny O. Mouse GLUT9: evidences for a urate uniporter. Am J Physiol Renal Physiol 297: F612–F619, 2009. doi:10.1152/ajprenal.00139.2009.
4. Bonventre JV. Kidney injury molecule-1: a translational journey. Trans Am Clin Climatol Assoc 125: 293–299, 2014.
5. Bouchard M, Souabni A, Busslinger M. Tissue-specific expression of cre recombinase from the Pax8 locus. Genesis 38: 105–109, 2004. doi: 10.1002/gene.20008.
6. Caulfield MJ, Munroe PB, O’Neill D, Witkowska K, Charchar FJ, Doblado M, Evans S, Eyheramendy S, Onipinla A, Howard P, Shaw-Hawkins S, Dobson RJ, Wallace C, Newhouse SJ, Brown M, Connell JM, Dominiczak A, Farrall M, Lathrop GM, Samani NJ, Kumari M, Marmot M, Brunner E, Chambers J, Elliott P, Kooner J, Laan M, Org E, Veldre G, Viigimaa M, Cappuccio FP, Ji C, Iacone R, Strazzullo P, Moley KH, Cheeseman C. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 5: e197, 2008. doi:10.1371/journal.pmed.0050197.
7. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382: 941–950, 2013. doi:10.1016/S0140-6736(13)60683-2.
8. Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, Tamai I. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biop-harm Drug Dispos 35: 391–404, 2014. doi:10.1002/bdd.1909.
9. +/glucose cotransporter SGLT2. JAmSoc Nephrol 28: 85–93, 2017. doi:10.1681/ASN.2015111282.
10. Eraly SA, Vallon V, Rieg T, Gangoiti JA, Wikoff WR, Siuzdak G, Barshop BA, Nigam SK. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 33: 180–192, 2008. doi:10.1152/physiolgenomics.00207.2007.
11. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266: 3008–3011, 1991. doi:10.1001/jama.1991.03470210076036.
12. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 15: 721–728, 2013. doi:10.1111/dom.12081.
13. Fu Y, Gerasimova M, Mayoux E, Masuda T, Vallon V. SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyper-filtration (Abstract). Diabetes 63, Suppl 1: A132, 2014.
14. +-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61: 187– 196, 2012. doi:10.2337/db11-1029.
15. Hosoyamada M, Ichida K, Enomoto A, Hosoya T, Endou H. Function and localization of urate transporter 1 in mouse kidney. J Am Soc Nephrol 15: 261–268, 2004. doi:10.1097/01.ASN.0000107560.80107.19.
16. Huang W, Patel R, Onishi A, Crespo-Masip M, Soleimani M, Freeman B, Vallon V. Tubular NHE3 is a determinant of the acute natriuretic and chronic blood pressure lowering effect of the SGLT2 inhibitor empagliflozin (Abstract). FASEB J 32, Suppl 1: 620.17, 2018.
17. Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, Stahl E, Weiner DE, Chertow GM. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis 71: 851–865, 2018. doi:10.1053/j.ajkd.2017.12.009.
18. Keembiyehetty C, Augustin R, Carayannopoulos MO, Steer S, Man-olescu A, Cheeseman CI, Moley KH. Mouse glucose transporter 9 splice variants are expressed in adult liver and kidney and are up-regulated in diabetes. Mol Endocrinol 20: 686–697, 2006. doi:10.1210/me.2005-0010.
19. Knight TF, Senekjian HO, Sansom S, Weinman EJ. Effects of intralu-minal D-glucose and probenecid on urate absorption in the rat proximal tubule. Am J Physiol Renal Fluid Electrolyte Physiol 236: F526–F529, 1979. doi:10.1152/ajprenal.1979.236.6.F526.
20. Lu Y, Nakanishi T, Tamai I. Functional cooperation of SMCTs and URAT1 for renal reabsorption transport of urate. Drug Metab Pharmacokinet 28: 153–158, 2013. doi:10.2133/dmpk.DMPK-12-RG-070.
21. Lytvyn Y, Škrtić M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 308: F77–F83, 2015. doi:10.1152/ajprenal.00555.2014.
22. +-D-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats. Pflugers Arch 469: 1545–1565, 2017. doi:10.1007/s00424-017-2056-1.
23. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, Frascerra S, Ciociaro D, Ferrannini E. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 9: 746–752, 1996. doi:10.1016/0895-7061(96)00098-2.
24. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44: 375–393, 2012. doi:10.3109/07853890.2011.560181.
25. + exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25: 2028–2039, 2014. doi:10.1681/ASN.2013060588.
26. Preitner F, Bonny O, Laverrière A, Rotman S, Firsov D, Da Costa A, Metref S, Thorens B. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci USA 106: 15501–15506, 2009. doi:10.1073/pnas.0904411106.
27. Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev 33: 5, 2017. doi:10.1002/dmrr.2886.
28. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon V. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306: F188–F193, 2014. doi:10.1152/ajprenal.00518.2013.
29. +-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 302: C1174–C1188, 2012. doi:10.1152/ajpcell.00450.2011.
30. Skeith MD, Healey LA, Cutler RE. Effect of phloridzin on uric acid excretion in man. Am J Physiol 219: 1080–1082, 1970. doi:10.1152/ajplegacy.1970.219.4.1080.
31. So A, Thorens B. Uric acid transport and disease. J Clin Invest 120: 1791–1799, 2010. doi:10.1172/JCI42344.
32. Ter Maaten JC, Voorburg A, Heine RJ, Ter Wee PM, Donker AJ, Gans RO. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci (Lond) 92: 51–58, 1997. doi:10.1042/cs0920051.
33. Thangaraju M, Ananth S, Martin PM, Roon P, Smith SB, Sterneck E, Prasad PD, Ganapathy V. c/ebpdelta Null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney. J Biol Chem 281: 26769–26773, 2006. doi:10.1074/jbc.C600189200.
34. Toyoki D, Shibata S, Kuribayashi-Okuma E, Xu N, Ishizawa K, Hosoyamada M, Uchida S. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. Am J Physiol Renal Physiol 313: F826–F834, 2017. doi:10. 1152/ajprenal.00012.2017.
35. Vallon V, Eraly SA, Rao SR, Gerasimova M, Rose M, Nagle M, Anzai N, Smith T, Sharma K, Nigam SK, Rieg T. A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol 302: F1293–F1299, 2012. doi:10.1152/ajprenal.00013.2012.
36. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104–112, 2011. doi:10.1681/ASN. 2010030246.
37. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60: 215–225, 2017. doi:10.1007/s00125-016-4157-3.
38. Völkl H, Geibel J, Rehwald W, Lang F. A microelectrode for continuous monitoring of redox activity in isolated perfused tubule segments. Pflugers Arch 400: 393–397, 1984. doi:10.1007/BF00587538.
39. +-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467: 1881–1898, 2015. doi:10.1007/s00424-014-1619-7.